The VA Primary – A Bellwether For the Country?
State AG Pulse | A FAIR Go For NY Consumers
Solicitors General Insights: A Deep Dive With Mississippi and Tennessee Solicitors General — Regulatory Oversight Podcast
Leadership and Innovation at the Illinois AG's Office — Regulatory Oversight Podcast
Podcast - Ohio State Senator Has a Bone to Pick with Court Ruling on Boneless Wings
State AG Pulse | The State AG: Both Advocate & Influencer
State AG Pulse | Swinging Through the Rust Belt, the Sun Belt and the South
Emerging Technology in the FY24 NDAA
El juicio presidencial en Colombia con Rossi Cruz
2024 Elections: The Race for the White House and Congress
Podcast: A Conversation with Andy Rotherham on Hot Topics in Education for 2023
Podcast - An Update on the Renewable Fuel Standard Final Rule
Stroock Presents: GOAT Town, Episode 2: “Bringing Some POP(S) to New York City Blocks”
2022 Midterm Election Update: Which Party Will Control the House and Senate?
Podcast: A Deep Dive into Consortia with Dan Sennott and Stephanie Halcrow
Since the recent Dobbs decision, which overturned Roe v. Wade, companies have been impacted nationwide and have several new legal angles to consider as it relates to their employees and their business
The Art of Making Policy
Orrick Public Policy Podcast #26 – A Conversation with the Minnesota State Senate Majority Leader Jeremy Miller
Episode 18 | Unpacking the Packing: A Perspective on the Efforts to Expand the Supreme Court
Over the first weeks of July 2025, the U.S. Food and Drug Administration (FDA) has issued several announcements heralding new policies and proposed regulatory changes that could dramatically impact the drug, biologics and...more
Goodwin’s 2025 Rare Disease Symposium, held on February 5 in Boston and virtually, gathered patient advocates and caregivers, providers, researchers, biotech and medtech leaders, investors, and policy experts to discuss the...more
Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that could affect biotech, pharmaceutical, and medical device companies in coming...more
Our FDA and Health Care Policy teams discuss how sponsors and manufacturers can prepare for legislative and regulatory changes that could come from the final Food and Drug Amendments (PDUFA VII) and what companies can do...more